EAACI Congress 2024

Back
31 May - 03 June 2024 Valencia, Spain

Flash talks on Hereditary Angioedema

Sunday 02 Jun, 15:00 PM - 16:30 PM Valencia, Spain
Palma Flash Talks
15:00
Lanadelumab Long-Term Effectiveness and Safety by Disease Activity: Pooled Analysis of the ENABLE and EMPOWER Studies
15:07
Burden of Disease and Health-Related Quality of Life Impairment in Adult Patients With Hereditary Angioedema: Results From a Multinational Survey
15:14
Analysis of prodromal symptoms and need for short-term prophylaxis in hereditary angioedema patients under long-term prophylaxis
15:21
Patient Reported Outcomes by Hereditary Angioedema Disease Activity: Pooled Analysis From the ENABLE and EMPOWER Studies
15:28
Genital Attacks in Hereditary Angioedema And Their Effects On Sexual Life
15:35
Understanding treatment switching patterns and continuation rates for patients with hereditary angioedema receiving lanadelumab: analysis of real-world data
15:42
Prospective monitoring of clinical outcomes and laboratory markers of hereditary angioedema in patients on long-term prophylaxis with lanadelumab: One-year follow-up
15:49
Under-representation and -reporting of race in global hereditary angioedema trials: A hidden yet alarming source of disparities
15:56
Long-term Real-Life Effectiveness and Tolerability of Lanadelumab in Hereditary Angioedema: The Bulgarian Experience
16:03
Comorbidities in hereditary angioedema patients in Canada: a quantitative survey study
16:10
Hereditary Angioedema (HAE) Patients Answer: Why Do Attacks Go Untreated?

Speakers